BerGenBio

Selective AXL inhibitors

Home  /  Media Centre  /  Presentations

SITC 2021, Rolf A. Brekken et al.

Share This Presentation

9th November 2021

AXL targeting with bemcentinib restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells

Share This Presentation

Latest News

News

BerGenBio Reports Third Quarter 2022 Financial Results and Provides Business Update

News

BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.